The purpose of this study is to find out if circulating tumor DNA (ctDNA) testing results can be used to determine if the usual approach or mFOLFIRINOX should be used to prevent colon cancer from returning in patients that are ctDNA positive and if the usual approach compared to ctDNA testing every 3 months should be used to prevent colon cancer from returning in patients that are ctDNA negative.
Learn more about the NRG-GI008 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
